Phaseline

Targets › FTSJ1

FTSJ1 (tRNA): drug programs, companies and trials

2 programs from 1 company in 2 trials: 2 Phase 2; Infectious disease.

Methylates the 2'-O-ribose of nucleotides at positions 32 and 34 of the tRNA anticodon loop of substrate tRNAs. Requisite for faithful cytoplasmic translation. (UniProt, Q9UET6)

Open in Phaseline: the race on FTSJ1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University Hospital, Basel, SwitzerlandCefazolin
Bacterial penicillin-binding protein inhibitor
FTSJ1Phase 2Complicated Staphylococcus Aureus (S. Aureus) Infections (CSAI)–
University Hospital, Basel, SwitzerlandFlucloxacillin (FLU) continuous infusion with TDM
Beta-lactam antibiotic; inhibits bacterial cell wall synthesis by binding to penicillin-bi
FTSJ1Phase 2Complicated Staphylococcus Aureus (S. Aureus) Infections (CSAI)–

Conditions

Complicated Staphylococcus Aureus (S. Aureus) Infections (CSAI) (2)

Modalities

small molecule (2)

Companies

University Hospital, Basel, Switzerland (2)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.